Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.
New drug kills mosquitos by blood poisoning
Latest NewsA drug named nitisinone, EU-approved for the treatment of metabolic diseases, also shows strong mosquito-killing properties. According to researchers headed by Lee Haines, it turns human blood toxic to Anopheles mosquitoes that transmit Plasmodium falciparum, the most deadly form of malaria.
Researchers crack the code of protein degradation
Latest NewsResearchers at the Max Planck Institute of Biochemistry (MPIB) and MRC Laboratory of Molecular Biology in Cambridge have developed and patented the new UbiREAD technology, which decodes the complex ubiquitin code that marks target proteins for E3 ligase-mediated degradation in cells.
Life Sciences Meets Lab Automation
AssociationsSLAS is pleased to bring together the laboratory automation and life sciences research communities at the SLAS Europe 2025 Conference & Exhibition at the Congress Center Hamburg, 20-22 May.
Boosting Startup Ecosystems
Sponsored PublicationsThe Technologiepark Heidelberg has been shaping Heidelberg‘s startup ecosystem with 100,000 sqm of lab and office spaces, individual startup support, and top events for over 40 years – offering ideal conditions for established companys and startups in the fields of life sciences, biotech, industry tech, and AI.
Enhancing macromolecule drug discovery with CDD
BackgroundThe landscape of macromolecule drug discovery is evolving rapidly, with oligonucleotides and peptides leading the way in innovative therapeutic applications. CDD Vault, a leading scientific data management system, significantly improves the way researchers manage macromolecule data by introducing a dedicated Macromolecule mode that seamlessly integrates with modern workflows.
European biotechs navigating a new financing environment
OpinionAfter the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging long-term financing trends as well as the recent events in the US, which may also impact the biotech industry.
New Chief Commercial Officer on board
AppointmentsCambridge-based 4basebio PLC announced the appointment of Gabe Longoria as Chief Commercial Officer.
Augustine Therapeutics NV raises €78m in Series A round
Latest NewsLeuven-based Augustine Therapeutics NV will use the proceeds from a €77.7m in Series A financing led by Novo Holdings and Jeito Capital to advance its preclinical HDAC6 inhibitor AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease to Phase I testing.
Trump’s win will affect the biotechnology sector
OpinionDuring the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?
The golden age of engineered therapeutic antibodies
OpinionTherapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.